Corvia Medical is revolutionizing the treatment of heart failure (HF) through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, Corvia is dedicated to transforming the standard of care for HF treatment, enabling patients to reclaim their lives.
The Corvia® Atrial Shunt (investigational device not available for commercial distribution in the United States) is a minimally invasive cardiac implant for patients suffering from symptomatic HF. Designed to reduce elevated left atrial pressure, the Corvia Atrial Shunt offers a therapeutic option for the millions of HF patients with an ejection fraction ≥40%. The shunt was granted FDA Breakthrough Device designation in 2019 and is currently the subject of the RESPONDER-HF confirmatory trial.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
NoACC.24 Learning Pathways? (select all that apply)
Heart Failure and Cardiomyopathies, Interventional and Structural CardiologyFirst time Exhibitor?
Yes